AIF1 and Alzheimer disease: In contrast, representative images of the double staining CD16/32, an M1 phenotype marker, with Iba-1 showed that CD16/32+/Iba-1+ cells in the cortex and hippocampus of PBM-treated AD rats were significantly decreased (Cortex: P = 0.00385; Hippocampus: P = 0.00012).